WO2014208987A1 - 안정성이 개선된 항체-약물 결합체 및 이의 용도 - Google Patents
안정성이 개선된 항체-약물 결합체 및 이의 용도 Download PDFInfo
- Publication number
- WO2014208987A1 WO2014208987A1 PCT/KR2014/005589 KR2014005589W WO2014208987A1 WO 2014208987 A1 WO2014208987 A1 WO 2014208987A1 KR 2014005589 W KR2014005589 W KR 2014005589W WO 2014208987 A1 WO2014208987 A1 WO 2014208987A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- drug
- drug conjugate
- mmaf
- conjugate
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 98
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 97
- 239000003814 drug Substances 0.000 claims abstract description 91
- 229940079593 drug Drugs 0.000 claims abstract description 86
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 56
- 238000009739 binding Methods 0.000 claims description 54
- 230000027455 binding Effects 0.000 claims description 53
- 239000000562 conjugate Substances 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 26
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 23
- 108010059074 monomethylauristatin F Proteins 0.000 claims description 22
- 208000023275 Autoimmune disease Diseases 0.000 claims description 15
- 229960000575 trastuzumab Drugs 0.000 claims description 14
- -1 acyl azide Chemical class 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 12
- 239000002254 cytotoxic agent Substances 0.000 claims description 11
- 150000001299 aldehydes Chemical class 0.000 claims description 10
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims description 9
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims description 9
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 8
- 231100000765 toxin Toxicity 0.000 claims description 8
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 7
- 231100000433 cytotoxic Toxicity 0.000 claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 150000008064 anhydrides Chemical class 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 6
- 229950000918 glembatumumab Drugs 0.000 claims description 6
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 6
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 5
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 5
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
- 230000001861 immunosuppressant effect Effects 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 4
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 4
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 claims description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 102000001301 EGF receptor Human genes 0.000 claims description 3
- 108060006698 EGF receptor Proteins 0.000 claims description 3
- 150000001502 aryl halides Chemical class 0.000 claims description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 3
- 229930195731 calicheamicin Natural products 0.000 claims description 3
- 150000001718 carbodiimides Chemical class 0.000 claims description 3
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 3
- 229930188854 dolastatin Natural products 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229940015043 glyoxal Drugs 0.000 claims description 3
- 150000002463 imidates Chemical class 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- 150000002540 isothiocyanates Chemical group 0.000 claims description 3
- 150000002924 oxiranes Chemical class 0.000 claims description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000624 procarbazine Drugs 0.000 claims description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 101800002638 Alpha-amanitin Proteins 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 239000012625 DNA intercalator Substances 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 2
- RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 claims description 2
- 102100035721 Syndecan-1 Human genes 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 229940110282 alimta Drugs 0.000 claims description 2
- 239000004007 alpha amanitin Substances 0.000 claims description 2
- CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 230000011278 mitosis Effects 0.000 claims description 2
- KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 claims description 2
- 239000003123 plant toxin Substances 0.000 claims description 2
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 claims description 2
- 229930013292 trichothecene Natural products 0.000 claims description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001099 trimetrexate Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- 229960005502 α-amanitin Drugs 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 claims 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229960000473 altretamine Drugs 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000011748 cell maturation Effects 0.000 claims 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims 1
- 229930000184 phytotoxin Natural products 0.000 claims 1
- 229930184737 tubulysin Natural products 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 20
- 239000002619 cytotoxin Substances 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 230000021615 conjugation Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 231100000304 hepatotoxicity Toxicity 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 206010019851 Hepatotoxicity Diseases 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 101100288143 Rattus norvegicus Klkb1 gene Proteins 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 230000007686 hepatotoxicity Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 4
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 102100031013 Transgelin Human genes 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 231100000226 haematotoxicity Toxicity 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000012510 peptide mapping method Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 238000000670 ligand binding assay Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000013365 molecular weight analysis method Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- LXEMXIOOAGRSRJ-PQUPALFMSA-N CCC(C)[C@@H](C(C)CC(N(CCC1)C1/C(/[C@@H](C)C(/N=C(\Cc1ccccc1)/C(O)=O)=O)=[O]\C)=O)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCCCC=O)=O)=O)=O Chemical compound CCC(C)[C@@H](C(C)CC(N(CCC1)C1/C(/[C@@H](C)C(/N=C(\Cc1ccccc1)/C(O)=O)=O)=[O]\C)=O)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCCCC=O)=O)=O)=O LXEMXIOOAGRSRJ-PQUPALFMSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229940122277 RNA polymerase inhibitor Drugs 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- MFRNYXJJRJQHNW-NARUGQRUSA-N monomethyl auristatin f Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)C([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-NARUGQRUSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000847 severe hepatotoxicity Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- WCFTYXWKCDJUFP-YJNPREOBSA-N vinpoline Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@H](C(=O)OCC(C)O)N5C2=C1 WCFTYXWKCDJUFP-YJNPREOBSA-N 0.000 description 1
- 229950009991 vinpoline Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention relates to an antibody-drug conjugate in which a drug is bound to an N-terminal amino acid residue of a heavy or light chain of the antibody, a method for preparing the same, and a use thereof.
- ADCs antibody-drug conjugates
- antibody-drug conjugates generally have a disadvantage of lower stability in vivo than natural antibodies, but have been developed to improve the low therapeutic effect, which is a disadvantage of natural antibodies, by combining with drugs.
- Drugs having specific effects, such as cytotoxins have been developed in various forms, and in particular, methods for inducing cancer cell death by combining cytotoxins with cancer cell specific antibodies are currently commercially available.
- DAR when the expression level of cancer cell surface antigen is low, in order to maintain high cytotoxicity, DAR should be maintained as high as possible.However, when DAR reaches 8, the half-life in the blood is reduced due to the effect of hydrophobic drugs bound to the antibody. Has the disadvantage of increasing and decreasing in vivo efficacy.
- the present inventors have made diligent efforts to develop an antibody-drug conjugate which can maintain the antigen-binding ability of the parent antibody equally and exhibit excellent anti-cancer effect while being less toxic by the drug and having excellent in vivo efficacy.
- the drug when the drug is bound to the N-terminus of the heavy or light chain of the antibody, the present invention was completed by finding out that it has excellent blood stability and anticancer activity while having less toxicity in vivo compared to the previously reported antibody-drug conjugate. It was.
- One object of the present invention is to provide an antibody-drug conjugate in which a drug is bound to a heavy or light chain N-terminal amino acid residue of the antibody.
- Another object of the present invention is to provide a method for preparing the antibody-drug conjugate.
- Still another object of the present invention is to provide a method for treating autoimmune disease, comprising administering the antibody-drug conjugate to a subject suspected of autoimmune disease.
- Another object of the present invention is to provide a method for selecting an antibody suitable for preparation with the antibody-drug conjugate.
- the method for preparing the antibody-drug conjugate of the present invention it is possible to prepare the antibody-drug conjugate having higher in vivo efficacy, stability and low toxicity.
- MMAF Monomethyl Auristatin F
- Figure 2 is a schematic view showing the structure of the homogeneous non-engineered monoclonal antibody-cytotoxin conjugate, the number and position of the binding.
- Fig. 3 shows the LC / MS profile of T-N-MMAF.
- Figure 4 is a diagram showing the results confirmed by peptide mapping the drug binding position in the prepared Trastzumab-N-MMAF (T-N-MMAF conjugate).
- Figure 5 is a diagram showing the SEC-HPLC chromatogram results of the prepared T-N-MMAF.
- FIG. 8 is a graph showing the results of comparing PK profiles of total / conjugate for each ADC.
- Figure 9 shows tumor growth curves formed by HCC1954 cell line in nude rat xenograft models.
- FIG. 10 is a diagram showing survival curves in a nude rat xenograft model experiment in which tumor size was set as an endpoint.
- FIG. 11 is a diagram showing changes in body weight and relative changes according to the administration of each ADC.
- FIG. 12 is a view showing the results of confirming the hepatotoxicity according to the administration of each ADC.
- FIG. 13 is a diagram showing changes in neutrophils and platelets according to the administration of each ADC.
- Fig. 14 shows the results of T-N-MMAE LC / MS analysis.
- Fig. 15 shows the Rat PK profile of T-N-MMAE.
- Fig. 16 shows the LC / MS profile of Brentuximab-N-MMAF (B-N-MMAF).
- Fig. 17 shows the results of analyzing the antigen binding ability of B-N-MMAF.
- Fig. 18 shows the conjugation profile of Lorvotuzumab-N-MMAF (L-N-MMAF).
- Fig. 19 shows the antigen binding force of L-N-MMAF.
- the present invention provides antibody-drug conjugates in which the drug is bound to the heavy or light chain N-terminal amino acid residues of the antibody.
- the term “antibody-drug conjugate (ADC)” refers to a form in which the drug and the antibody are chemically linked without lowering the biological activity of the antibody and the drug.
- the antibody-drug conjugate is a form in which the drug is bound to the N-terminal amino acid residue of the heavy chain and / or light chain of the antibody, specifically, the drug is attached to the N-terminal ⁇ -amine group of the heavy or / and light chain of the antibody. The combined form.
- an antibody-drug conjugate formed by a previously reported cysteine bond, an antibody-drug conjugate formed by a thiol bond, and lysine Compared with the antibody-drug conjugate formed by the binding, it is confirmed that both the efficacy and stability in vivo are excellent and less toxic, so that the N-terminus of the heavy or light chain of the antibody has all the advantages of efficacy, stability and low toxicity. It can be identified.
- a schematic diagram of such an antibody-drug conjugate according to the present invention is shown in FIG. 2.
- N-terminus refers to the amino terminus, ie, the N-terminus, of the heavy or light chain of an antibody, and refers to a position capable of binding a drug for the purposes of the present invention. Examples include, but are not limited to, the amino acid residues at or near the N-terminus as well as the amino acid residues at the N-terminus, specifically the first amino acid residue of the heavy or light chain of the antibody, and more. Specifically, it refers to the ⁇ -amine group of the first amino acid of the heavy or light chain of the antibody, but is not limited thereto.
- the antibody-drug conjugates of the present invention may have the advantage of ensuring homogeneity through site specific binding and / or number specific binding of the antibody and drug.
- the number corresponding to the most optimal drug-antibody ratio (DAR) to the N-terminal amino acid residue for each antibody for example, 1 to 8 drugs can bind.
- DAR drug-antibody ratio
- the term “homogeneity” refers to a case where the bonding ratio and the bonding position of two materials are homogeneous in a conjugate formed by combining two materials.
- the present invention is not limited to the meaning that only the case where the binding ratio and the binding position are exactly the same is included.
- the conjugate is homogeneous, it becomes homogeneous as a whole and can accurately measure the efficacy according to the dosage, thereby standardizing its dosage, frequency of administration, and the like.
- antibody refers to a protein molecule that acts as a receptor for an antigen that specifically recognizes an antigen, including an immunoglobulin molecule that is immunologically reactive with a specific antigen.
- Polyclonal antibodies, monoclonal Antibody fragments include antibodies, full-length antibodies, and antigen binding domains.
- the full length antibody is a structure having two full length light chains and two full length heavy chains, each of which is linked by a heavy chain and a disulfide bond.
- the total antibody includes IgA, IgD, IgE, IgM and IgG, and IgG is a subtype, including IgG1, IgG2, IgG3 and IgG4.
- the antibody fragment refers to a fragment having an antigen binding function, and includes Fab, Fab 'F (ab') 2 , scFv, Fv and the like.
- the Fab has one antigen binding site in a structure having a variable region of the light and heavy chains, a constant region of the light chain and a first constant region of the heavy chain (CH1).
- F (ab ') 2 antibodies are produced when the cysteine residues of the hinge region of Fab' form disulfide bonds.
- Fv (variable fragment) means a minimum antibody fragment having only the heavy chain variable region and light chain variable region.
- Double-chain Fv is a disulfide bond is linked to the heavy chain variable region and light chain variable region, and short-chain Fv (scFv) is generally covalently linked to the variable region of the heavy chain and the light chain through a peptide linker.
- Such antibody fragments can be obtained using proteolytic enzymes (e.g., the entire antibody can be restricted to papain and Fabs can be obtained and pepsin can be used to obtain F (ab ') 2 fragments). Can be produced through genetic recombination techniques.
- the antibodies of the present invention may be native antibodies or recombinant antibodies.
- a native antibody refers to an antibody that has not been genetically modified, and may have a significantly low risk of immunogenicity that the genetically engineered antibody may have in vivo.
- Recombinant antibody means a genetically engineered antibody, there is a feature that can add the antigen binding ability or the desired characteristics through genetic engineering.
- the term "genetic engineering” refers to the act of changing an amino acid sequence, and includes manipulation of a polypeptide having an amino acid sequence that is somewhat different from the original sequence polypeptide encoding the amino acid sequence.
- Amino acid sequence variants will contain amino acid sequences in which amino acids have been substituted, deleted or externally inserted at specific positions within the amino acid sequence.
- the antibody of the present invention may be one that specifically recognizes a cell surface antigen that is internalized in the cell when the antibody binds to the antigen.
- the drug bound to the antibody specifically the cytotoxic drug is introduced into the cell by the properties, the efficacy of the drug may be high, but It is not limited.
- the antibody of the present invention may specifically bind to a cancer cell surface antigen or a tissue surface antigen from which an autoimmune disease has occurred.
- cancer cell surface antigen means that a substance that is not produced or is not exposed to the cell surface of the normal cell is more exposed to the surface of the cancer cell than the material or the normal cell that is specifically exposed to the cell surface. It refers to a lot of substances. When the substance is recognized by an antibody, it is expressed as an antigen.
- the cancer cell surface antigens of the present invention include, without limitation, cancer cell surface substances that antibodies of the present invention can specifically recognize, for example CD19, CD20, CD30, CD33, CD37, CD22, CD56, CD70, CD74, CD138, Muc-16, mesothelin, HER2, HER3, glycoprotein NMB (GPNMB), IGF-1R, B cell maturation antigen (BCMA), prostate-specific membrane antigen (PSMA), epipithelial cell adhesion molecule (EpCAM) and EGFR It may be selected from the group consisting of (epidermal growth factor receptor), more specifically may be selected from the group consisting of HER2, CD30, CD56 and GPNMB. However, it is not limited thereto.
- Trastuzumab a type of anti-HER2 antibody that recognizes Her2, CD56, and GPNMB, Lorvotuzumab, a type of anti-CD56 antibody, and a type of anti-CD30 antibody
- Brentuximab and Glembatumumab a type of anti-GPNMB antibody
- the term "drug” may mean any substance having a specific biological activity in a cell, which includes a compound, DNA, RNA, peptide, and the like. It may be in a form including a reactor capable of reacting and crosslinking with an ⁇ -amine group, and also includes a form in which a linker including a reactor capable of reacting with and reacting with an ⁇ -amine group is linked. In this case, the drug may be specifically linked to the N-terminal amino acid residue of the antibody by a linker, but is not limited thereto.
- the linker refers to a chemical moiety comprising an atomic chain that covalently binds a drug to an antibody.
- the linker is prepared in a form linked to the drug, and has a reactor at the linker end that can be linked to the antibody.
- Examples of the reactor capable of reacting and crosslinking with the ⁇ -amine group are not particularly limited as long as they can be crosslinked by reacting with the N-terminal ⁇ -amine group of the heavy or light chain of an antibody, and are known in the art. All kinds of reactions with groups include but are not limited to isothiocyanate, isocyanates, acyl azides, NHS esters, sulfonyl chlorides, and aldehydes.
- aldehyde glyoxal, epoxide, oxirane, carbonate, aryl halide, imidoester, carbodiimide, anhydride ( anhydride) and fluorophenyl ester, and the like
- reactors are aldehyde and NHS ester, but are not particularly limited thereto.
- Such reactors may be combined with an amine group by an acylation or alkylation reaction, but are not particularly limited thereto.
- the antibody-drug conjugate of the present invention may be an immunoconjugate in which a drug linked to a linker having an aldehyde reactor is site-specifically and number-specifically bound to an amino acid residue at the N terminus of the antibody.
- Aldehyde reactors are effective for site-specific binding of drugs to amino acid residues, particularly ⁇ -amines, at the N terminus of antibodies by minimizing nonspecific reactions.
- the final product resulting from reductive alkylation by aldehyde bonds is much more stable than linked by amide bonds.
- Aldehydes have the property of selectively reacting with N-terminal ⁇ -amines at low pH.
- the conjugate of the present invention has homogeneity in which the drug is specifically linked to the N-terminal ⁇ -amine of the antibody. Therefore, the problem of not being able to guarantee uniform drug efficacy and quality caused by heterogeneity of the number and location of the binding of the conjugate of the existing antibody and the drug is not particularly limited thereto.
- the inventors of the present invention when the reaction is carried out at pH 6.0 or less during the binding reaction to link the site-specific cytotoxic drug to the ⁇ -amine of the antibody, ⁇ that the cytotoxic drug is present in the lysine residue It was found that binding to amines can be minimized.
- the drug includes all substances capable of causing cell death, cell proliferation, immune activity, activation of specific signaling, including inhibition of immunity, or inhibition of specific signaling, etc., and the drug is particularly cytotoxic. It may be a drug or an immunosuppressant.
- cytotoxic drug refers to any substance, such as a compound, having a cytotoxic or cytostatic effect.
- Cytotoxic means an effect of inhibiting or lowering the function of cells to cause cell destruction
- inhibiting cell proliferation means an effect of limiting cell growth functions, such as restriction of cell growth or cell proliferation.
- the cytotoxic drug is a microtubulin structure forming inhibitor, a mitosis inhibitor, an RNA polymerase inhibitor, a topoisomerase inhibitor, a DNA intercalators, a DNA alkylator (DNA alkylator), a chemotherapeutic agent capable of functioning as a ribosomal inhibitor, and the like, a protein toxin capable of functioning enzymatically, and a radioisotope.
- Examples include maytansinoids, mayurisinin, auristatin, dolastatin, tubelysine, tuchelysin, calicheamicin, pyrrolobenzodiazepines, doxorubicin , Duocamycin, carboplatin (paraplatin), cisplatin, cyclophosphamide, ifosfamide, nidran, nitrogen Mustard (mecloethamine hydrochloride) [nitrogen mustar (mechlorethamine HCL)], bleomycin, mitomycin C, cytarabine, flurouracil, gemcitabine, tree Trimetrexate, methotrexate, etoposide, vinpoline, vinblastine, vinorelbine, alimta, altamine, procarbazine (procarbazine), taxol, taxotere, topotecan topotecan, irinotecan, trichothecene, CC1065, alpha-aman
- immune inhibitor refers to any compound that has the effect of reducing an immune response. This means a substance capable of antagonizing an immune-causing substance or suppressing substances (cytokines such as interleukins) involved in an immune response.
- cytokines such as interleukins
- Trastuzumab, Robototuzumab, Brentuximab, and Glembatumumab as representative antibodies are used as model antibodies, and the N-terminal thereof is used as a representative antibody.
- Monomethyl auristatin F (MMAF) and monomethyl aristatin E (MMAE) were used as representative cytotoxic drugs to bind, respectively (Examples 1 and 2).
- Trastuzumab was reacted with MMAF or MMAE at a pH of 6.0 to prepare an antibody-drug conjugate in which the drug was bound to its N-terminus, and the antibody-drug conjugate was capable of antigen binding and cytotoxicity of the antibody even after drug binding.
- the present invention provides a method for producing the antibody-drug conjugate.
- the antibody-drug conjugate and its components are as described above.
- the production method includes the step of connecting the drug to the N-terminal ⁇ -amine group of the heavy or light chain of the antibody by reacting the antibody with a drug comprising a reactor capable of reacting and crosslinking the ⁇ -amine group .
- the preparation method may further comprise the step of separating the antibody-drug conjugate from the reaction product containing the antibody and drug that do not form a conjugate.
- the antibody and the drug in the preparation method may be connected at pH 4.0 or more and pH 6.5 or less, more specifically, pH 5.5 or more and pH 6.5 or less, and more specifically, at pH 6.0.
- the low pH has the advantage that the binding between the aldehyde present in the drug or the linker thereof and the N-terminal ⁇ -amine of the antibody can occur specifically.
- the separation process of the antibody-drug conjugate may be performed through various methods known in the art, for example, may be performed through a chromatography process including size exclusion chromatography, but is not particularly limited thereto.
- the present invention provides a composition comprising the antibody-drug conjugate.
- the composition comprises the form of a pharmaceutical composition for treating cancer or autoimmune disease comprising the antibody-drug conjugate.
- the antibody may specifically bind to a cancer cell surface antigen or a tissue surface antigen from which an autoimmune disease has occurred.
- the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier.
- the antibodies, drugs, cancer cell surface antigens and tissue surface antigens from which autoimmune diseases have occurred are the same as described above.
- cancer includes, without limitation, the type of cancer, for example esophageal cancer, stomach cancer, colorectal cancer, rectal cancer, oral cancer, pharyngeal cancer, laryngeal cancer, lung cancer, colon cancer, breast cancer, cervical cancer, endometrial cancer, ovary Cancer, prostate cancer, testicular cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, bone cancer, connective tissue cancer, skin cancer, brain cancer, thyroid cancer, leukemia, Hodgkin's disease, lymphoma, or multiple myeloma hematoma cancer.
- the cancer that can be treated can be selected according to the type of antibody specific for the cancer cell surface antigen.
- autoimmune disease includes any type of autoimmune disease targeted by the antibody-drug conjugate of the present invention, for example, rheumatoid arthritis, systemic scleroderma, systemic lupus erythematosus, atopic dermatitis , Psoriasis, alopecia areata, asthma, Crohn's disease, Bechesi's disease, Sjogren's syndrome, Gilia-Barré syndrome, chronic thyroiditis, multiple sclerosis, multiple myositis, ankylosing spondylitis, fibrous histitis or nodular polyarteritis.
- the term "pharmaceutically acceptable carrier” refers to a carrier or diluent that does not irritate an organism and does not inhibit the biological activity and properties of the administered compound.
- Acceptable pharmaceutical carriers in compositions formulated as liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary.
- the carrier is not particularly limited, but oral administration may include a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersant, a stabilizer, a suspending agent, a dye, a perfume, and the like.
- a buffer Preservatives, analgesic agents, solubilizers, isotonic agents, stabilizers and the like can be mixed and used.
- bases, excipients, lubricants, preservatives and the like can be used for topical administration.
- Formulations of the compositions of the present invention can be prepared in a variety of mixtures with the pharmaceutically acceptable carriers described above.
- it may be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, they may be prepared in unit dosage ampoules or multiple dosage forms. And other solutions, suspensions, tablets, pills, capsules, sustained release preparations and the like.
- suitable carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl Cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
- fillers, anti-coagulants, lubricants, wetting agents, fragrances, preservatives and the like may be further included.
- compositions of the present invention are tablets, pills, powders, granules, capsules, suspensions, solvents, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, and lyophilization according to conventional methods, respectively. It may have any of the formulations selected from the group consisting of formulations and suppositories.
- composition may be formulated in a unit dosage form suitable for intrabody administration of a patient according to a conventional method in the pharmaceutical field, preferably in the form of a formulation useful for the administration of a peptide medicine, and is commonly used in the art.
- the conjugate may be used in admixture with a number of carriers (pharmaceutically acceptable) such as saline or organic solvents, and carbohydrates such as glucose, sucrose or dextran (ascorbic acid) to increase stability or absorption.
- carriers pharmaceutically acceptable
- carbohydrates such as glucose, sucrose or dextran (ascorbic acid)
- Antioxidants such as ascorbic acid or glutathione, chelating agents, small molecule proteins or other stabilizers can be used as medicaments.
- the present invention provides a method of treating cancer or autoimmune disease using the antibody-drug conjugate or the composition.
- the antibody may be one that specifically binds to a cancer cell surface antigen, and the drug may be a cancer treatment drug.
- the antibody may specifically bind to a tissue surface antigen from which an autoimmune disease has occurred, and the drug may be an autoimmune disease therapeutic drug.
- the antibodies and drugs are the same as described above.
- the method may be a method for treating a cancer or an autoimmune disease comprising administering the pharmaceutical composition to a subject in need thereof, wherein the type of antibody-drug conjugate and carrier used is described above. Same as bar.
- the composition may be administered in single or multiple amounts in a pharmaceutically effective amount.
- the composition may be administered in the form of a liquid, powder, aerosol, capsule, enteric skin tablets or capsules or suppositories.
- Routes of administration include, but are not limited to, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, endothelial administration, oral administration, topical administration, intranasal administration, pulmonary administration, rectal administration, and the like.
- the antibody which is a protein
- the pharmaceutical composition may be administered by any device in which the active agent may migrate to the target cell.
- the pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents.
- compositions comprising the antibody-drug conjugates of the invention are administered in a pharmaceutically effective amount.
- “Pharmaceutically effective amount” means an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention, wherein an effective dose level is the severity of the disease, the activity of the drug, the age of the patient, Body weight, health, sex, sensitivity to the drug of the patient, time of administration of the composition of the invention used, route of administration and rate of release, duration of treatment, elements including drugs used or combined with the composition of the invention used and other medical fields Can be determined according to well-known factors.
- the present invention provides a method for selecting an antibody suitable for preparation with the antibody-drug conjugate.
- the preparation of the antibody-drug conjugate according to the present invention it is possible to search for and select an antibody suitable for effectively preparing the antibody-drug conjugate by binding the drug to the N-terminus of the antibody, specifically, ⁇ -amine.
- the intra-anti-HER2 antibody which is an anti-HER2 antibody
- the intra-anti-HER2 antibody is used to confirm that the cytotoxins in which the linker is present bind to the antibody in a site-selective manner.
- the above antibodies were constructed using expression vector amino acid sequence information, and expressed, cultured, and purified through stable cell line construction or transient expression in CHO cell lines.
- MMAF Monomethyl Auristatin F
- XcessBioscience XcessBioscience
- the antibody was exchanged to 100 mM potassium phosphate pH5.49 buffer solution and concentrated to about 7.1 mg / ml. Thereafter, MMAF (Lego Chem Bioscience, Korea), which is connected to a linker having an aldehyde reactor, was dissolved in 50% DMSO (dimethyl sulfoxide) solvent to obtain 2.5 mg / ml.
- DMSO dimethyl sulfoxide
- Control antibody-drug conjugates prepared by conventional techniques include cysteine binding (Cys conjugation, Thiomab (HC-A114C) + Mal-C6-MMAF), thiol binding (Mal-C6-MMAF), and lysine binding (SMCC linker, SH- C6-MMAF).
- the thiol-binding antibody was reduced to TCEP at pH 8.0 and then reacted at 0 ° C. for 3 hours with Mal-C4-MMAF. After the reaction, cysteine was added to further react, and the reaction was terminated. The reaction was terminated by replacing with 1 ⁇ PBS using a G25 Desalting column (GE healthcare, USA).
- Cysteine-binding antibody was activated by the cysteine of the purified antibody, followed by conjugation by adding Mal-C6-MMAF to a process similar to thiol-binding antibody.
- the conjugate of lysine binding antibody was prepared with reference to Immunogen Corporation Patent (WO2005037992). First, the antibody and SMCC linker were reacted, and the unreacted SMCC was removed through buffer exchange. The antibody-SMCC conjugate was reacted with SH-C4-MMAF (Concortis bioscience, USA) containing a thiol group to prepare an antibody-SMCC-MMAF conjugate.
- SH-C4-MMAF Conscortis bioscience, USA
- T-N-MMAF The molecular weight of the antibody-drug conjugate (T-N-MMAF) was confirmed by LC-MS analysis. Theoretical value of the molecular weight upon binding of the drug (MMAF) used is 824.54 Da and the molecular weight of trastuzumab is 145 kDa. Therefore, mass spectrometry also confirmed whether the drug bound to the antibody and the number of drugs bound to one molecule of the antibody at the same time.
- T-N_MMAF conjugate The drug-binding position in the prepared T-N_MMAF conjugate was confirmed through peptide mapping.
- the T-N-MMAF ADC of DAR 3.2 prepared in Example 3 was denatured to Rapigest (Waters) and then reacted with trypsin (Roche) to make a section.
- the reaction was separated by ACQUITY UPLC PST (BEH) C18 column and each separated peak was subjected to mass spectrometry using a Waters Synapt G2-S Q / TOF system to determine which sequence it corresponds to and the results are shown in FIG. 4.
- the purity of the monomer was 98.8%, confirming the purity suitable for the potency test, and no fragmentation or cross-linking was observed.
- BIAcore TM Biacore TM
- a surface plasmon resonance surface plasmon resonance
- a control antibody a natural antibody was used.
- Antigen (ErbB2) avidity was analyzed using Biacore T200, and each antibody was immobilized on a CM5 sensor chip (GE healthcare) using an amine coupling kit, followed by ErbB2 (R & D systems) 50, 16.67, 5.56, 1.85, 0.62. , Injected at a rate of 30 uL / min at a concentration of 0.21 nM, and measured and analyzed the on / off rate to obtain kD (M).
- Test 1 (10 -10 M) Test 2 (10 -10 M) Average (10 -10 M) Trastuzumab 1.3 2.2 1.8 TN-MMAF (DAR 1.6) 1.2 0.9 1.1 TN-MMAF (DAR 3.2) 1.1 0.7 0.9 0.9
- anti-proliferative assays were performed using HER2 expressing tumor cell lines BT474, HCC1954, SKOV-3, and JIMT-1 cell lines. Incubate each cell and suspend at 1 * 10 5 cells / ml and load 100 ⁇ l into a 96 well plate. After 3 hours of incubation in a cell incubator, 100 ⁇ l of antibody-cytotoxin conjugates at various concentrations per well were added and incubated in the cell incubator for 4 days.
- Table 6 sample Relative content of monoclonal antibody (storage 7 days,%) Relative content of binder (7 days storage,%) Relative content of DAR (7 days retention,%) Trastuzumab 90.0 - - TN-MMAF 89.3 90.5 101.4 TC-MMAF 49.2 32.3 65.6 Thiomab-mmaf 69.9 59.5 85.1
- Rat Pharmacokinetics Rat PK
- ADCs T-K-MMAF, T-C-MMAF, T-N-MMAF
- trastuzumab were intravenously injected into female Sprague-Dawley rats at a 2.5 mg / kg dose. Blood was collected after 0.05 hours, 0.5 hours, 1 hour, 6 hours, 24 hours, 72 hours, 168 hours, 240 hours, and 336 hours after material administration.
- a total antibody assay for analyzing all antibodies that bind to ErbB2 in the blood and a conjugated antibody assay for analyzing antibodies in which drug binding is maintained were performed by ELISA.
- Binding antibody assay proceeded in a similar manner to that described above, after coating a 96-well microplate with an anti-MMAF antibody (YoungInfrontier), the sample was placed in a plate and reacted for 1 hour at a temperature of 37 °C. Subsequently, biotinylated ErbB2 (ACROBIOSYSTEMS, USA), streptavidin-HRP, and TMB were sequentially added to determine the concentration of the binding antibody by measuring absorbance at 450 nm. The results are shown in FIGS. 6 to 8 and Table 7 below. Indicated.
- TNM DAR approximately 1.6 and 3.2
- TCM DAR approximately 3.7
- TKM DAR approximately 3.9
- the antibody according to the present invention was excellent in anticancer effect compared to the control and comparative antibody results.
- Single-dose toxicity studies were conducted using SD rats to determine whether stability that depends on the manufacturing technique of the ADC affects toxicity.
- Three ADCs were each administered once intravenously at high doses of 200 mpk.
- single antibody and MMAF were also administered at the exposure of 200 mpk.
- Body weight was measured daily from the time of administration of the test substance to the end of the experiment (12 days).
- Blood and biochemical analyzes were performed 5 days after administration. Measures are AST, ALT, Neutrophil and Platelet for hepatotoxicity and representative hematologic toxicity.
- T-C-MMAF, T-K-MMAF group showed a significant weight loss compared to the T-N-MMAF group and the rest of the group.
- the T-C-MMAF-treated group died after 8 days except for one.
- Blood biochemical analysis was performed on blood collected on day 5 after administration to compare hepatotoxicity. 12 were performed using Au480 (Beckman coulter, USA) chemistry analyzer, AST (Aspartate Aminotransferase) and ALT (Alanine Aminotransferase), which are indicators of hepatotoxicity.
- the T-N-MMAF group according to the present invention showed a change that does not differ significantly from other controls, including PBS was observed that did not cause acute or severe hepatotoxicity.
- significant increases were observed in the T-C-MMAF and T-K-MMAF groups, indicating hepatotoxicity due to drug administration.
- Hematological analysis was performed using Hemavet 950 FS (Drew Scientific Inc., USA) hematology analyzer on blood collected on day 5 after administration, as the major clinical toxicity of currently approved ADCs is shown as hematological characteristics, The result is shown in FIG.
- the number of neutrophils (Neutrophil), T-N-MMAF group did not show a significant change compared to the control group containing PBS, did not cause acute and severe hematologic toxicity.
- the T-C-MMAF group showed a significant decrease and the T-K-MMAF group showed a marked increase, which was estimated to decrease immediately after administration and then rise again. Therefore, it could be concluded that the drug administration caused rapid hematological toxicity in these two groups.
- the T-N-MMAF-administered group was slightly reduced to show a difference compared to other controls including PBS.
- the T-C-MMAF and T-K-MMAF groups showed a sharp decrease, indicating that rapid toxicity was caused by the administration material.
- the method of preparing the antibody-drug conjugate of the present invention can be used for various antibody-drug conjugates. To this end, it was intended to confirm the function by applying to various drugs or various antibodies and various antibody forms.
- Example 3 According to the method of Example 3, a conjugate was made between MMAE (XcessBioscience, USA) and an antibody, and the results of molecular weight analysis by LC / MS to determine DAR are shown in FIG. 14 and Table 8 below.
- the serum stability of the T-N-MMAE ADC was evaluated.
- the concentration of ADC in each sample was measured by total antibody assay using ELISA, and the change of DAR was measured by LC / MS.
- a PK measurement test using an SD rat was performed similarly to Example 6 described above. Briefly, 2.5 mg / pk ADC was administered to female SD rats and blood was drawn after 12, 30, 1, 6, 24, 3, 7, 10, 14, 17 and 21 days. The concentration was determined according to the method described above by dividing the total antibody and binding antibody using the ELISA technique.
- TN-MMAE showed a profile that is not significantly different from the parent antibody in both the total antibody and the binding antibody, and similar stability to MMAF even when the antibody-drug complex was prepared with MMAE.
- Table 10 TN-MMAE showed a profile that is not significantly different from the parent antibody in both the total antibody and the binding antibody, and similar stability to MMAF even when the antibody-drug complex was prepared with MMAE.
- MMAE Similar stability to MMAF even when the antibody-drug complex was prepared with MMAE.
- the measured IC 50 ranged from 0.33-3.76 nM, which is similar to the activity (0.47 nM) on the BT474 cell line of trastuzumab / MMAE thiol conjugates reported in the literature. Therefore, it can be said that the N-terminal selective binding method using ⁇ -amine according to the present invention can be applied to other types of drugs.
- N-terminal binding is performed on three anticancer antibodies (Brentuximab, Lorvotuzumab, and Glembatumumab) to measure DAR analysis and in vitro stability. It was.
- Example 3 Brentusimab-N-MMAF (B-N-MMAF) was prepared according to the method of Example 3 with brentushimab expressed from the CHO cell line.
- the prepared ADC exhibited an LC / MS profile as shown in FIG. 16 and Table 12 below. Species up to D0-D6 were detected and the DAR was calculated to be 2.90.
- the binding ability to the antigen was measured and compared by ELISA method.
- Antigen CD30 R & D systems
- PBST PBS + 0.05% Tween 20
- HRP conjugated anti-human kappa light chain antibody was diluted 1000-fold and placed in a plate and reacted at 37 ° C. for 1 hour.
- TMB TMB (Sigma) was added and developed for 10 minutes.
- Anti-proliferation assays were performed using Karpas-299, L-540 cell lines, CD30 expressing cell lines, to confirm the in vitro efficacy of the prepared antibody-cytotoxin conjugate.
- each cell was cultured and suspended at 1 * 10 5 cells / ml and loaded into 100 wells in 96 well plates. After 3 hours of incubation in a cell incubator, 100 ⁇ l of antibody-cytotoxin conjugates at various concentrations per well were added thereto, and the cells were incubated for 4 days in the cell incubator.
- CCK-8 (Dojindo) was diluted 1:10 and treated in each well, and then wrapped in aluminum foil and reacted in a cell incubator for 2 to 5 hours. Absorbance was measured at 450 nm using a SpectraMax 190 microplate reader, and the results are shown in Table 13 below.
- Robotuzumab-N-MMAF (L-N-MMAF) was prepared according to the method of Example 3 above with robotuzumab temporarily expressed from CHO cells.
- the prepared ADC showed a conjugation profile as shown in FIG. 18 and Table 14, and the DAR was determined to be 3.33.
- Antigen CD56 R & D systems, 2408-NC-050
- Antigen CD56 R & D systems, 2408-NC-050
- anti-proliferation assay was performed using OPM-2 cell line. Each cell was cultured and suspended at 1 * 10 5 cells / ml and loaded into 100 ⁇ l into a 96 well plate. After 3 hours of incubation in a cell incubator, 100 ⁇ l of antibody-cytotoxin conjugates of various concentration sections were added per well, and the cells were cultured in a cell incubator for 4 days. CCK-8 (Dojindo) was diluted 1:10 and treated in each well, then wrapped in foil and reacted in a cell incubator for 2-5 hours. Absorbance was measured at 450 nm using a SpectraMax 190 microplate reader, and the results are shown in Table 15.
- L-N-MMAF antibody according to the present invention showed a cytotoxicity of 42-53nM level.
- anti-proliferation assay was performed using SK-MEL-2 cell line, a skin cancer cell line. Each cell was cultured and suspended at 1 * 10 5 cells / ml and loaded into 100 ⁇ l into a 96 well plate. After 3 hours of incubation in a cell incubator, 100 ⁇ l of antibody-cytotoxin conjugates at various concentrations per well were added thereto, and the cells were incubated for 4 days in the cell incubator. CCK-8 (Dojindo) was diluted 1:10 and treated in each well, then wrapped in foil and reacted in a cell incubator for 2-5 hours. Absorbance was measured at 450 nm using a SpectraMax 190 microplate reader, and the results are shown in Table 16.
- G-N-MMAF according to the present invention showed a cytotoxicity of 3-5nM level.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
항체-약물 결합체 | ||
결합 종류 | 결합 조건 | 결합체 명칭 (Trastuzumab, MMAF 사용 시) |
Cys 결합 | Thiomab(HC A114C), Mal-C6-MMAF | Thiomab-MMAF |
Thiol 결합 | Mal-C6-MMAF | T-C-MMAF |
Lys 결합 | SMCC 링커, SH-C6-MMAF | T-K-MMAF |
Amine 결합 | ALD-C6-MMAF (약산성 pH 조건) | T-N-MMAF |
No. of bound drug | Mass (Da) | Relative intensity(%) | Da |
0 | 145179.5 | 1.8 | - |
1 | 146005.3 | 10.7 | 825.8 |
2 | 146833.2 | 21.2 | 827.9 |
3 | 147661.1 | 25.4 | 827.9 |
4 | 148488.9 | 21.0 | 827.8 |
5 | 149317.0 | 12.5 | 828.1 |
6 | 150145.5 | 5.0 | 828.5 |
7 | 150964.2 | 2.3 | 818.7 |
DAR | 3.219 | ||
DAR = Sum(Intensity(%) x No. of Drug / 100)Drug moiety mass : 828 Da |
트립신 단편(Trypsin fragment) | Ratio | |
중쇄-N말단 | EVQLVESGGGLVQPGGSLR (서열번호 1) | 46% |
경쇄-N말단 | DIQMTQSPSSLSASVGDR (서열번호 2) | 29% |
중쇄-CH2 | THTCPPCPAPELLGGPSVFLFPPKPKDTLMISR (서열번호 3) | 17% |
그외 | - | 8% |
시료 | 항원 결합력 | ||
Test 1 (10-10 M) | Test 2 (10-10 M) | 평균 (10-10 M) | |
트라스투주맙 | 1.3 | 2.2 | 1.8 |
T-N-MMAF (DAR 1.6) | 1.2 | 0.9 | 1.1 |
T-N-MMAF (DAR 3.2) | 1.1 | 0.7 | 0.9 |
Cell line | Cytotoxicity (IC50 (pM)) | ||
T-N-MMAF(DAR 3.2) | T-C-MMAF(DAR 3.6) | T-K-MMAF(DAR 3.9) | |
HCC1954 | 40 | 22 | 45 |
SKOV-3 | 104 | 59 | N.D. |
JIMT1 | 253 | 98 | 727 |
BT474 | 116 | 49 | 77 |
시료 | 단일클론항체의 상대적 함량(보관 7일, %) | 결합체의 상대적 함량(보관 7일, %) | DAR의 상대적 함량(보관 7일, %) |
Trastuzumab | 90.0 | - | - |
T-N-MMAF | 89.3 | 90.5 | 101.4 |
T-C-MMAF | 49.2 | 32.3 | 65.6 |
Thiomab-MMAF | 69.9 | 59.5 | 85.1 |
랫트에 ADC를 2.5mg/kg 용량으로 투여한 다음, 측정한 PK 파라미터 | ||||||
Treatment (n=5, each)2-compartment modeling | Total Ab | Conjugated Ab | ||||
AUC(hr*㎍/ml) | T1/2(hr) | Cmax(㎍/ml) | AUC(hr*㎍/ml) | T1/2(hr) | Cmax(㎍/ml) | |
Trastzumab | 6964.9 | 115.7 | 128.1 | - | - | - |
T-N-MMAF | 6795.7 | 122.1 | 111.2 | 6813.2 | 118.3 | 112.4 |
T-C-MMAF | 5933.5 | 111.6 | 94.3 | 4315.4 | 84.6 | 93.7 |
T-K-MMAF | 4324.3 | 65.1 | 157.5 | 3781.7 | 53.2 | 190.0 |
T-N-MMAE의 DAR별 화학종 분포도 및 평균 DAR | |||
No. of drug | Mass (Da) | Relative content (%) | Delta mass |
D0 | N/D | N/D | |
D1 | 146061.05 | 6.3 | |
D2 | 146863.77 | 14.3 | 802.72 |
D3 | 147672.80 | 23.3 | 809.03 |
D4 | 148484.33 | 24.2 | 811.53 |
D5 | 149297.30 | 16.5 | 812.97 |
D6 | 150112.25 | 8.6 | 814.95 |
D7 | 150922.84 | 6.8 | 810.59 |
DAR | 3.83 |
μg/ml | % | DAR | % | |
Day 0 | 364.8 | 100% | 3.17 | 100% |
Day 3 | 346.9 | 95% | 3.33 | 105% |
Day 7 | 294.8 | 81% | 3.28 | 103% |
T-N-MMAE 의 rat PK 파라미터. | ||||
Group | AUC(hr*㎍/ml) | Conjugate/Total ratio | half-life (hr) | Conjugate/Total ratio |
trastuzumab | 5868.83 | 169.6 | ||
T-N-MMAF (T) | 6688.95 | 191.8 | ||
T-N-MMAF (C) | 6871.71 | 103% | 203.3 | 106% |
T-N-MMAE (T) | 5639.24 | 173.9 | ||
T-N-MMAE (C) | 5690.96 | 101% | 163.7 | 94% |
* 시험간 비교를 위해 trastuzumab과 T-N-MMAF를 포함하였다. |
Her2 발현 종양 세포주에 대한 T-N-MMAE의 세포 독성 | |||
IC50[nM] | |||
#1 | #2 | Average | |
HCC1954 | 0.39 | 0.26 | 0.33 |
SKOV-3 | 3.04 | 2.62 | 2.83 |
JIMT1 | 4.00 | 3.51 | 3.76 |
BT474 | 0.56 | 0.70 | 0.63 |
No. of bound drug | Mass (Da) | Relative content (%) | Delta mass(Da) |
D0 | 145208.6 | 3.1 | |
D1 | 146034.9 | 14 | 826.3 |
D2 | 146863.3 | 24.4 | 828.4 |
D3 | 147692 | 26.4 | 828.7 |
D4 | 148520.7 | 18.2 | 828.7 |
D5 | 149349.7 | 9.3 | 829 |
D6 | 150177.5 | 4.7 | 827.8 |
DAR | 2.90 |
Cell line | IC50(pM) |
Karpas-299 | 32.2 |
L-540 | 37.1 |
No. of bound drugs | Mass (Da) | Relative content (%) | Delta mass (Da) |
D0 | 147001.5 | 3.3 | |
D1 | 147830.8 | 10.8 | 829.3 |
D2 | 148657.9 | 18.6 | 827.1 |
D3 | 149486.6 | 22.7 | 828.7 |
D4 | 150315.4 | 20.1 | 828.8 |
D5 | 151144.7 | 13.7 | 829.3 |
D6 | 151973.5 | 7 | 828.8 |
D7 | 152803 | 3.7 | 829.5 |
DAR | 3.329 |
IC50[nM] | ||
OPM-2 | L-N-MMAF DAR 2.5 | 52.9 |
L-N-MMAF DAR 3.3 | 41.9 |
SK-MEL-2 | IC50(nM) |
G-N-MMAF DAR 2.2 | 5.47 |
G-N-MMAF DAR 3.4 | 3.36 |
Claims (21)
- 항체의 중쇄 또는 경쇄의 N-말단 아미노산 잔기에 세포독성 약물(cytotoxic drug)이 결합된, 항체-약물 결합체(antibody-drug conjugate, ADC).
- 제1항에 있어서,상기 항체의 중쇄 또는 경쇄의 N-말단의 α-아민기에 세포독성 약물이 결합된 것인, 항체-약물 결합체.
- 제2항에 있어서,α-아민기와 반응하여 가교할 수 있는, 세포독성 약물의 반응기를 통하여 세포독성 약물이 항체에 연결된 형태인 것인, 항체-약물 결합체.
- 제3항에 있어서,상기 α-아민기와 반응하여 가교할 수 있는 반응기는 아이소티오시아네이트(isothiocyanate), 아이소시아네이트(isocyanates), 아실 아자이드(acyl azide), NHS 에스터(NHS ester), 설포닐 클로라이드(sulfonyl chloride), 알데하이드(aldehyde), 글리옥살(glyoxal), 에폭사이드(epoxide), 옥시레인(oxirane), 칼보네이트(carbonate), 아릴 할라이드(aryl halide), 이미도에스터(imidoester), 카보이미드(carbodiimide), 안하이드라이드(anhydride) 및 플루오로페닐 에스터(fluorophenyl ester)로 이루어진 군에서 선택된 것인, 항체-약물 결합체.
- 제1항에 있어서,상기 항체는 전장 항체, 또는 항원 결합 도메인을 포함하는 항체 단편 형태인 것인, 항체-약물 결합체.
- 제5항에 있어서,상기 항체는 IgG, scFv, Fv, Fab, Fab' 및 F(ab')2로 이루어진 군으로부터 선택된 형태를 가지는 것인, 항체-약물 결합체.
- 제1항에 있어서,상기 세포독성 약물은 마이크로튜불린(microtubulin) 구조 형성 억제제, 유사분열(meiosis) 억제제, RNA 중합효소 억제제, 토포아이소머라아제(topoisomerase) 억제제, DNA 인터컬레이터(DNA intercalators), DNA 알킬레이터(DNA akylator), 리보솜 억제제, 방사선 동위원소 및 독소로 이루어진 군으로부터 선택되는 것인, 항체-약물 결합체.
- 제7항에 있어서,상기 세포독성 약물은 메이탄시노이드(maytansinoid), 오리스타틴(auristatin), 돌라스타틴(dolastatin), 튜브라이신(tubulysin), 칼리케아미신(calicheamicin), 피롤로벤조디아제피네스(pyrrolobenzodiazepines), 독소루비신(doxorubicin), 듀오카마이신(duocamycin), 카보플라틴(파라플라틴)[Carboplatin(paraplatin)], 시스플라틴(cisplatin), 시클로포스파미드(cyclophosphamide), 이포스파미드(ifosfamide), 니드란(nidran), 질소머스타드(메클로에타민 염산염)[nitrogen mustar(mechlorethamine HCL)], 블레오마이신(bleomycin), 미토마이신 C(mitomycin C), 시타라빈(cytarabine), 플루로우라실(flurouracil), 젬시타빈(gemcitabine), 트리메트렉세이트(trimetrexate), 메토크렉세이트(methotrexate), 에토포시드(etoposide), 빈블라스틴(vinblastine),비노렐빈(vinorelbine), 알림타(alimta), 알트레타민(altretamine), 프로카바진(procarbazine), 탁솔(taxol), 탁소텔(taxotere), 토포테칸(topotecan), 이리노테칸(irinotecan), 트리코테센(trichothecene), CC1065, 알파-아마니틴(alpha-amanitin) 균체 외독소 및 식물독소로 이루어진 군으로부터 선택된 것인, 항체-약물 결합체.
- 제8항에 있어서,상기 오리스타틴은 모노메틸 오리스타틴 E(Monomethyl auristatin E) 또는 모노메틸 오리스타틴 F(Monomethyl auristatin F)인 것인, 항체-약물 결합체.
- 제1항에 있어서,상기 항체는 암세포 표면 항원에 특이적으로 결합하는 것인, 항체-약물 결합체.
- 제10항에 있어서,상기 암세포 표면 항원은 CD19, CD20, CD30, CD33, CD37, CD22, CD56, CD70, CD74, CD138, Muc-16, mesothelin, HER2, HER3, GPNMB(glycoprotein NMB), IGF-1R, BCMA(B cell maturation antigen), PSMA(prostate-specific membrane antigen), EpCAM(Epithelial cell adhesion molecule) 및 EGFR(epidermal growth factor receptor)로 이루어진 군에서 선택된 것인, 항체-약물 결합체.
- 제1항에 있어서,상기 항체는 항-HER2 항체, 항-CD30 항체, 항-CD56 항체 및 항-GPNMB(glycoprotein NMB) 항체로 이루어진 군으로부터 선택된 것인, 항체-약물 결합체.
- 제12항에 있어서,상기 항체는 트라스투주맙(Trastuzumab), 로보투주맙(Lorvotuzumab), 브렌투시맙(Brentuximab) 및 글렘바투무맙(Glembatumumab)으로 이루어진 군에서 선택된 것인, 항체-약물 결합체.
- 항체의 중쇄 또는 경쇄의 N-말단 아미노산 잔기에 면역억제제가 결합된, 항체-약물 결합체(antibody-drug conjugate, ADC).
- α-아민기와 반응하여 가교할 수 있는 반응기를 포함하는 세포독성 약물 또는 면역억제제와 항체를 반응시켜, 항체의 중쇄 또는 경쇄의 N-말단의 α-아민기에 세포독성 약물 또는 면역억제제를 연결시키는 단계를 포함하는, 제1항 내지 제14항 중 어느 한 항의 항체-약물 결합체의 제조방법.
- 제15항에 있어서,상기 제조방법은 추가로 결합체를 형성하지 않은 항체, 및 세포독성 약물 또는 면역 억제제를 포함하는 반응 산물로부터 항체-약물 결합체를 분리하는 단계를 포함하는 것인, 제조방법.
- 제15항에 있어서,상기 α-아민기와 반응하여 가교할 수 있는 반응기는 아이소티오시아네이트(isothiocyanate), 아이소시아네이트(isocyanates), 아실 아자이드(acyl azide), NHS 에스터(NHS ester), 설포닐 클로라이드(sulfonyl chloride), 알데하이드(aldehyde), 글리옥살(glyoxal), 에폭사이드(epoxide), 옥시레인(oxirane), 칼보네이트(carbonate), 아릴 할라이드(aryl halide), 이미도에스터(imidoester), 카보이미드(carbodiimide), 안하이드라이드(anhydride) 및 플루오로페닐 에스터(fluorophenyl ester)로 이루어진 군에서 선택된 것인 제조방법.
- 제1항 내지 제13항 중 어느 한 항의 항체-약물 결합체를 포함하는, 암 치료용 약학적 조성물.
- 제14항의 항체-약물 결합체를 포함하는, 자가면역질환의 치료용 약학적 조성물.
- 제1항 내지 제13항 중 어느 한 항의 항체-약물 결합체를 암 의심 개체에 투여하는 단계를 포함하는, 암의 치료 방법.
- 제14항의 항체-약물 결합체를 자가면역질환 의심 개체에 투여하는 단계를 포함하는, 자가면역질환의 치료 방법.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2916202A CA2916202C (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
JP2016523642A JP6208864B2 (ja) | 2013-06-24 | 2014-06-24 | 安定性が改善された抗体−薬物結合体およびこれの用途 |
EP14817162.2A EP3015116B1 (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
US14/898,126 US10071170B2 (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
CN201480035895.0A CN105377307B (zh) | 2013-06-24 | 2014-06-24 | 具有改进的稳定性的抗体-药物缀合物及其用途 |
BR112015032200A BR112015032200A2 (pt) | 2013-06-24 | 2014-06-24 | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo |
AU2014299561A AU2014299561B2 (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
RU2016102116A RU2670748C9 (ru) | 2013-06-24 | 2014-06-24 | Конъюгаты антител с лекарственными агентами, обладающие улучшенной стабильностью, и их применение |
US16/059,761 US20180360986A1 (en) | 2013-06-24 | 2018-08-09 | Antibody-drug conjugate having improved stability and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0072686 | 2013-06-24 | ||
KR20130072686 | 2013-06-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/898,126 A-371-Of-International US10071170B2 (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
US16/059,761 Division US20180360986A1 (en) | 2013-06-24 | 2018-08-09 | Antibody-drug conjugate having improved stability and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014208987A1 true WO2014208987A1 (ko) | 2014-12-31 |
Family
ID=52142250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/005589 WO2014208987A1 (ko) | 2013-06-24 | 2014-06-24 | 안정성이 개선된 항체-약물 결합체 및 이의 용도 |
Country Status (10)
Country | Link |
---|---|
US (2) | US10071170B2 (ko) |
EP (1) | EP3015116B1 (ko) |
JP (1) | JP6208864B2 (ko) |
KR (1) | KR101641206B1 (ko) |
CN (2) | CN110251683A (ko) |
AU (1) | AU2014299561B2 (ko) |
BR (1) | BR112015032200A2 (ko) |
CA (1) | CA2916202C (ko) |
RU (1) | RU2670748C9 (ko) |
WO (1) | WO2014208987A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10111966B2 (en) | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
US10434185B2 (en) | 2017-01-20 | 2019-10-08 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201811292RA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cells |
JP7222347B2 (ja) * | 2017-04-28 | 2023-02-15 | 味の素株式会社 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
MX2019015057A (es) * | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
US10976241B2 (en) * | 2017-09-08 | 2021-04-13 | Regeneran Pharmaceuticals, Inc. | Methods of assessing antibody-drug conjugates |
CN110090308B (zh) * | 2018-01-30 | 2023-03-24 | 四川科伦博泰生物医药股份有限公司 | 制备偶联物的方法 |
MX2020010110A (es) | 2018-03-28 | 2020-11-06 | Mitsubishi Tanabe Pharma Corp | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. |
JP7273858B2 (ja) * | 2018-06-15 | 2023-05-15 | シャンハイ ミラコーケン インコーポレイティド | 癌を治療するための方法と材料 |
JP2021528364A (ja) * | 2018-06-26 | 2021-10-21 | エービーエル バイオ インコーポレイテッド | 抗bcma抗体及びその用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037992A2 (en) | 2003-10-10 | 2005-04-28 | Immunogen, Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR20070037575A (ko) * | 2004-06-01 | 2007-04-05 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
WO2009026274A1 (en) * | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
US7723485B2 (en) * | 2007-05-08 | 2010-05-25 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
US20100183636A1 (en) * | 2003-02-20 | 2010-07-22 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL97776A (en) | 1990-04-19 | 2000-10-31 | Res Dev Foundation | Composition comprising a conjugate of a ZME antibody and a biological response modifier |
US20030215421A1 (en) | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
ATE293996T1 (de) * | 1998-10-13 | 2005-05-15 | Immunomedics Inc | Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren |
DE60121733T2 (de) * | 2000-02-24 | 2007-08-09 | Philogen S.P.A. | Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen |
KR100514119B1 (ko) | 2000-02-28 | 2005-09-13 | 신닛뽄세이테쯔 카부시키카이샤 | 성형성이 우수한 강관 및 그의 제조방법 |
US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
CA2493221C (en) * | 2002-07-24 | 2008-11-18 | F. Hoffmann-La Roche Ag | Polyethylene glycol aldehyde derivatives |
US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
AU2007240315A1 (en) * | 2006-04-20 | 2007-11-01 | Amgen Inc. | GLP-1 compound/glucagon antibody compositions |
PL2446904T3 (pl) * | 2006-05-30 | 2015-10-30 | Genentech Inc | Przeciwciała anty-CD22, ich immunokoniugaty oraz ich zastosowania |
US20100021379A1 (en) * | 2006-06-29 | 2010-01-28 | The Regents Of The University Of California | Chemical Antibodies for Immunotherapy and Imaging |
AU2007286451A1 (en) | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
MX2010005830A (es) | 2007-11-30 | 2010-09-14 | Bristol Myers Squibb Co | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. |
US20110053157A1 (en) | 2008-02-01 | 2011-03-03 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
JP5511686B2 (ja) * | 2008-12-26 | 2014-06-04 | 協和発酵キリン株式会社 | 抗cd4抗体 |
MX2011010265A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
ES2829423T3 (es) | 2009-04-20 | 2021-05-31 | Kyowa Kirin Co Ltd | Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo |
BR112013007160A2 (pt) * | 2010-09-29 | 2016-06-14 | Philogen Spa | ligante tiazolidina para a conjugação de fármacos a anticorpos |
CA2819187A1 (en) * | 2010-11-29 | 2012-06-07 | National Research Council Of Canada | Covalently dimerized bivalent binding agents |
US9540433B2 (en) | 2011-02-01 | 2017-01-10 | Genmab A/S | Human antibodies and antibody-drug conjugates against CD74 |
RU2619180C2 (ru) * | 2011-09-01 | 2017-05-12 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Антитела к xcr1 человека |
KR101426134B1 (ko) * | 2011-09-26 | 2014-08-06 | 한화케미칼 주식회사 | 항 igf-1r 단일클론 항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물 |
KR20130057959A (ko) * | 2011-11-24 | 2013-06-03 | 한화케미칼 주식회사 | 항 her2 단일클론항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물 |
WO2013122950A1 (en) | 2012-02-13 | 2013-08-22 | Wuyi Kong | Nprcps, pfdncs and uses thereof |
KR20150006000A (ko) * | 2012-05-01 | 2015-01-15 | 제넨테크, 인크. | 항-pmel17 항체 및 면역접합체 |
KR20130138608A (ko) * | 2012-06-11 | 2013-12-19 | 한화케미칼 주식회사 | 위치 특이적 항체-싸이토톡신 결합체 및 이의 용도 |
KR20150007922A (ko) | 2013-07-12 | 2015-01-21 | 권영아 | 루테리알의 형태특성을 이용한 질병의 진단방법 |
JP2017505448A (ja) | 2014-01-14 | 2017-02-16 | チョイ ウォンチョルCHOI, Won Cheol | ルテリアルの形態特性を用いた癌予防剤または抗癌剤のスクリーニング方法 |
-
2014
- 2014-06-24 KR KR1020140077630A patent/KR101641206B1/ko active IP Right Grant
- 2014-06-24 AU AU2014299561A patent/AU2014299561B2/en active Active
- 2014-06-24 JP JP2016523642A patent/JP6208864B2/ja active Active
- 2014-06-24 WO PCT/KR2014/005589 patent/WO2014208987A1/ko active Application Filing
- 2014-06-24 RU RU2016102116A patent/RU2670748C9/ru active
- 2014-06-24 CA CA2916202A patent/CA2916202C/en active Active
- 2014-06-24 EP EP14817162.2A patent/EP3015116B1/en active Active
- 2014-06-24 CN CN201910506833.8A patent/CN110251683A/zh active Pending
- 2014-06-24 CN CN201480035895.0A patent/CN105377307B/zh active Active
- 2014-06-24 BR BR112015032200A patent/BR112015032200A2/pt not_active IP Right Cessation
- 2014-06-24 US US14/898,126 patent/US10071170B2/en active Active
-
2018
- 2018-08-09 US US16/059,761 patent/US20180360986A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100183636A1 (en) * | 2003-02-20 | 2010-07-22 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
WO2005037992A2 (en) | 2003-10-10 | 2005-04-28 | Immunogen, Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR20070037575A (ko) * | 2004-06-01 | 2007-04-05 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
US7723485B2 (en) * | 2007-05-08 | 2010-05-25 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
WO2009026274A1 (en) * | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
Non-Patent Citations (2)
Title |
---|
See also references of EP3015116A4 |
ZOLOT, R. S. ET AL.: "Antibody-drug conjugates", NATURE REVIEWS DRUG DISCOVERY, vol. 12, April 2013 (2013-04-01), pages 259 - 260, XP055303640 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10111966B2 (en) | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
US10434185B2 (en) | 2017-01-20 | 2019-10-08 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
Also Published As
Publication number | Publication date |
---|---|
RU2016102116A (ru) | 2017-07-28 |
US10071170B2 (en) | 2018-09-11 |
KR101641206B1 (ko) | 2016-07-22 |
JP6208864B2 (ja) | 2017-10-04 |
US20160136300A1 (en) | 2016-05-19 |
CN105377307B (zh) | 2019-09-24 |
CA2916202C (en) | 2019-07-02 |
EP3015116A4 (en) | 2017-03-08 |
KR20150000843A (ko) | 2015-01-05 |
AU2014299561A1 (en) | 2016-01-21 |
CA2916202A1 (en) | 2014-12-31 |
JP2016523900A (ja) | 2016-08-12 |
AU2014299561B2 (en) | 2017-06-08 |
BR112015032200A2 (pt) | 2017-11-21 |
CN110251683A (zh) | 2019-09-20 |
US20180360986A1 (en) | 2018-12-20 |
EP3015116B1 (en) | 2020-02-26 |
RU2670748C2 (ru) | 2018-10-25 |
EP3015116A1 (en) | 2016-05-04 |
RU2670748C9 (ru) | 2018-12-13 |
CN105377307A (zh) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014208987A1 (ko) | 안정성이 개선된 항체-약물 결합체 및 이의 용도 | |
AU2019229076B2 (en) | Anti-TIGIT antibodies and uses thereof | |
AU2018271751B2 (en) | Anti-human interleukin-2 antibodies and uses thereof | |
WO2015152618A1 (ko) | 면역글로불린 fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 | |
WO2020184944A1 (ko) | 위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트 | |
KR20160113623A (ko) | 항체-약물 접합체 및 면역독소 | |
WO2018174544A2 (ko) | Muc1에 특이적으로 결합하는 항체 및 그의 용도 | |
WO2019050362A2 (ko) | 인간 dlk1에 대한 항체 및 이의 용도 | |
WO2017030370A1 (ko) | 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도 | |
CN114173825A (zh) | 抗体-药物偶联物及其在治疗中的应用 | |
WO2019066603A1 (ko) | 효력이 향상된 지속성 단백질 결합체 | |
CN115515642A (zh) | 抗cd56抗体-药物偶联物及其在治疗中的用途 | |
WO2019212253A1 (ko) | C-met에 특이적으로 결합하는 항체 및 그의 용도 | |
WO2021201654A1 (ko) | Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물 | |
WO2020004937A1 (ko) | 항-bcma 항체-약물 접합체 및 그 용도 | |
WO2021101349A1 (ko) | Ror1 및 b7-h3에 결합하는 항체, 이를 포함하는 항체-약물 접합체 및 그 용도 | |
WO2022245186A1 (ko) | Ror1 및 b7-h3에 결합하는 항체-약물 접합체 및 그 용도 | |
WO2016084993A1 (ko) | 신규 EGFRvIII 항체 및 이를 포함하는 조성물 | |
WO2019022563A2 (ko) | 이두로네이트 2-설파타제 결합체 | |
WO2013176516A1 (ko) | 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도 | |
WO2020071881A1 (ko) | Pdgf 수용체에 대한 항체 및 이의 용도 | |
WO2018105988A1 (ko) | 면역반응이 약화된 결합체 | |
WO2024043643A1 (ko) | Il2 변이체 및 이를 포함하는 단백질 복합체 | |
WO2024096577A1 (ko) | Fc 결합성 유닛을 포함하는 화합물 및 이를 이용하여 제조된 컨쥬게이트 | |
WO2023157989A1 (ko) | 항체-약물 접합체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14817162 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14898126 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2916202 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014817162 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016523642 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015032200 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014299561 Country of ref document: AU Date of ref document: 20140624 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016102116 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112015032200 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015032200 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151222 |